[Intensification of radio-hormone therapy for prostate cancer]

Historically, prostate cancer radiotherapy relied on conventional fractionation of 2 Gy per session over several weeks to limit toxicity to healthy tissues. Technological advances in imaging and treatment precision have enabled the development of hypofractionated schedules, involving fewer sessions, while maintaining similar efficacy. Combining radiotherapy with hormone therapy improves outcomes by increasing tumor cell sensitivity to radiation. The addition of abiraterone or enzalutamide to the treatment plan for some very high-risk patients further improves survival rates. However, these treatments may cause bone, metabolic, cardiovascular, and sexual side effects, requiring multidisciplinary management.